Patents by Inventor David A. Bumcrot

David A. Bumcrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic compositions
    Patent number: 10669544
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: June 2, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10)
    Publication number: 20200017849
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Application
    Filed: February 19, 2019
    Publication date: January 16, 2020
    Inventors: Morgan Lee MAEDER, David A. BUMCROT, Shen SHEN
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20190354055
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpinal gene, and methods of using such dsRNA compositions to inhibit expression of Serpinal.
    Type: Application
    Filed: July 17, 2019
    Publication date: November 21, 2019
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica Sehgal, David Bumcrot, Brian Bettencourt
  • ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT
    Publication number: 20190292595
    Abstract: The invention relates to methods and assays for determining the activity of a composition comprising a therapeutic gene administered to a subject.
    Type: Application
    Filed: February 6, 2019
    Publication date: September 26, 2019
    Inventors: Dinah Sah, David A. Bumcrot, Alfica Sehgal
  • THERAPEUTIC COMPOSITIONS
    Publication number: 20190264207
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Application
    Filed: March 14, 2019
    Publication date: August 29, 2019
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, David BUMCROT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS
    Publication number: 20190249157
    Abstract: Disclosed herein are genome editing systems and genetic constructs that targets a herpes simplex virus (HSV) viral gene comprising one Cas9 molecule, and a gRNA molecule, and compositions and cells comprising such genome editing systems and genetic constructs. Also provided are methods for using the genome editing systems, genetic constructs, compositions and cells for genome engineering (e.g., altering a HSV viral gene), and for preventing, treating or reducing HSV infection.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 15, 2019
    Applicants: EDITAS MEDICINE, INC., DUKE UNIVERSITY
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot, Bryan R. Cullen
  • COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE
    Publication number: 20190201550
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: August 2, 2018
    Publication date: July 4, 2019
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME
    Publication number: 20190136230
    Abstract: Provided are CRIS PR/CAS-related methods, compositions and components for editing a target nucleic acid sequence, or modulating expression of a target nucleic acid sequence, and applications thereof in connection with cancer immunotherapy comprising adoptive transfer of engineered T cells or T cell precursors.
    Type: Application
    Filed: May 6, 2017
    Publication date: May 9, 2019
    Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.
    Inventors: Blythe SATHER, G. Grant WELSTEAD, David A. BUMCROT, Ari E. FRIEDLAND, Jon JONES, Morgan L. MAEDER, Chris NYE, Eugenio Marco RUBIO, Ruth SALMON
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY
    Publication number: 20190134221
    Abstract: Disclosed herein are vectors that targets a dystrophin gene, encoding at least one Cas9 molecule or a Cas9 fusion protein, and at least one gRNA molecule (e.g., two gRNA molecules), and compositions and cells comprising such vectors. Also provided are methods for using the vectors, compositions and cells for genome engineering (e.g., correcting a mutant dystrophin gene), and for treating DMD.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 9, 2019
    Inventors: David A. Bumcrot, Nicholas C. Huston, Joshua C. Tycko, Jacqueline Robinson-Hamm, Charles A. Gersbach
  • Therapeutic compositions
    Patent number: 10273477
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: April 30, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
    Publication number: 20190119685
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Application
    Filed: September 4, 2018
    Publication date: April 25, 2019
    Inventors: David A. Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression
    Publication number: 20190106694
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: April 3, 2018
    Publication date: April 11, 2019
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)
    Patent number: 10253312
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 9, 2019
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, David A. Bumcrot, Shen Shen
  • Compositions and methods for inhibiting expression of TMPRSS6 gene
    Patent number: 10100312
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: October 16, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: David A. Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS
    Publication number: 20180251770
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Application
    Filed: April 30, 2018
    Publication date: September 6, 2018
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10)
    Publication number: 20180195058
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 12, 2018
    Inventors: Morgan Lee MAEDER, David A. BUMCROT, Shen SHEN
  • COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE
    Publication number: 20180155789
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 7, 2018
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 9963700
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 8, 2018
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20180120749
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: December 15, 2017
    Publication date: May 3, 2018
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica SEHGAL, David BUMCROT, Brian BETTENCOURT
  • CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS
    Publication number: 20180112213
    Abstract: CRISPR/Cas-related compositions and methods which provide for efficient gene editing of eukaryotic cells using modified gRNAs.
    Type: Application
    Filed: March 25, 2016
    Publication date: April 26, 2018
    Applicants: Editas Medicine, Inc., Editas Medicine, Inc.
    Inventors: Gordon Grant Welstead, Jennifer Leah Gori, Jack Michael Heath, David A. Bumcrot